Key result
Anlotinib plus systemic chemotherapy achieves 17-month survival in a patient with refractory cardiac intimal sarcoma.
Why the study?
Primary cardiac intimal sarcoma is a rare, highly malignant tumor with an extremely poor prognosis and no established clinical treatment guidelines.
Does anlotinib combined with chemotherapy improve overall survival in a patient with refractory primary cardiac intimal sarcoma?
Does anlotinib combined with chemotherapy improve overall survival in a patient with refractory primary cardiac intimal sarcoma?
Anlotinib combined with chemotherapy may be a promising therapeutic option for refractory primary cardiac intimal sarcoma, achieving a 17-month overall survival in this case.
May extend options in refractory cardiac intimal sarcoma; leaves open confirmation in prospective trials.
Introduction: Primary cardiac intimal sarcoma (CIS) is a rare and highly malignant soft tissue tumor associated with an extremely poor prognosis. To date, there are no established treatment guidelines for CIS in clinical practice. Case Presentation: A 44-year-old man was diagnosed with left atrial intimal sarcoma. Forty-two days after radical surgical resection, he developed local recurrence accompanied by brain and gluteus medius metastases. The patient first received emergency radiotherapy for intracranial metastases, followed by six cycles of systemic chemotherapy with ifosfamide and epirubicin, combined with targeted therapy using anlotinib. Ultimately, he achieved an overall survival (OS) of 17 months. Conclusion: To our knowledge, this is the first report describing the therapeutic efficacy of anlotinib in cardiac intimal sarcoma. This case highlights the potential role of anlotinib as a promising therapeutic option for this rare and aggressive malignancy.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2025) studied this question. Anlotinib combined with systemic chemotherapy resulted in an overall survival of 17 months in a patient with refractory primary cardiac intimal sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: